GenBody

GenBody

 

ounded in 2012 with the pursuit for human and global health, GenBody Inc.

creates innovative technologies for the development of raw materials for diagnostic use.

Founded in 2012 with the pursuit for human and global health, GenBody Inc. creates innovative technologies for the development of raw materials for diagnostic use. We offer diagnostic total solution such as rapid diagnostic tests (RDTs), fluorescent immuno-diagnostic tests, ELISA, molecular diagnostic tests (MDx) and clinical chemistry.

With over 20 years combined experience in the diagnostic industry and through vast bio-networks between several key institutes, universities, and hospitals, our core strength is in R&D. we specialize in developing monoclonal antibodies and recombinant antigens in-house at our facility in South Korea.

We also have patented technologies including fluorescent immuno-diagnostics, which will be one of the major IVD technologies of the future.

Our Mission statement is to bring Technology to Your life.
We continuously develop innovative diagnostics and pharmaceutical technologies for improving your quality of life.

  • 2018
    • May

      Launch of Arbovirus total solution (PCR+RDT)

    • Mar

      Expected launch of 11 F-RDTs & its analyzer

    • Mar

      Completion of second building expansion

    • Jan

      Expected launch of CCR (Clinical Chemistry Reagents) & Equipment: GOT, GPT, CRP, TP, > 63 kinds

  • 2017
    • Aug

      Completion of Cheonan HQ and first research center in Chungnam

    • Aug

      Launch of Arbovirus rapid diagnostic tests (12 parameters)

    • Jan

      Product quality certification for Chikungunya and Syphilis through Bahiafarma

  • 2016
    • Oct

      Contract to export and supply Zika diagnostic test (3.5 million tests) and quality certification for Chikungunya, Dengue IgG/IgM, NS1 Ag through Bahiafarma

    • Jun

      First in the world to be registered with the Brazilian government through Bahiafarma for Zika IgG/IgM rapid diagnostic test.

    • May

      Quality certification for Zika NS1 Ag rapid diagnostic test

    • Mar

      Development and evaluation of Chikungunya IgM diagnostic kits

    • Mar

      Launch of veterinary diagnostic tests for 36 parameters (The world’s largest quantities) and qGB analyzer (Hainan, China)

  • 2015
    • Dec

      First company to develop Zika RDT for humans in the world (Zka IgG/IgM RDT, Zika NS1 Ag RDT)

    • Nov

      First company to develop MERS-CoV RDT for humans in the world

    • Nov

      Second investment capital 500 million KRW

    • Oct

      Establishment of GenBody International Inc. in China

    • Jul

      Patent for exclusive use of mobile F-ICT (Korea USA)

    • Feb

      Exclusive License of diagnostic technology used Fullerene dye (Korea, USA, Japan, Germany)

  • 2014
    • Dec

      ISO13485 Certification

    • Jun

      Development of Cardiac Markers (TnI, CKMB, Myo, D-dimer)

    • Apr

      Development of markers for febrile disease (Leptospira, Tsutsugamushi, Hantanvirus)

    • Apr

      Approval of WHO Round 5 quality test for Malaria

  • 2013
    • Jun

      Development of Cancer markers (AFP, CEA, PSA, FOB)

    • Mar

      Patent for F-ICT ( Korea, USA, China )

    • Mar

      Patent for diagnosis method of fluorescence-based coumarin ( Korea, USA, China )

  • 2012
    • Oct

      Established GenBody Venture Startup in DanKook University